Toll Free: 1-888-928-9744

Benign Prostatic Hyperplasia - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Benign Prostatic Hyperplasia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 5, 6, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Benign Prostatic Hyperplasia Overview 10 Therapeutics Development 11 Pipeline Products for Benign Prostatic Hyperplasia - Overview 11 Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12 Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13 Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 15 Benign Prostatic Hyperplasia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Benign Prostatic Hyperplasia - Products under Development by Companies 20 Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 22 Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 23 Addex Therapeutics Ltd 23 AndroScience Corporation 24 Aphios Corporation 25 BCWorld Pharm Co. Ltd. 26 Biolab Farmaceutica Ltda 27 Chong Kun Dang Pharmaceutical Corp. 28 Dongkook Pharmaceutical Co., Ltd. 29 Hanmi Pharmaceuticals, Co. Ltd. 30 Health Ever Bio-Tech Co., Ltd. 31 Jeil Pharmaceutical Co., Ltd. 32 Kaken Pharmaceutical Co., Ltd. 33 MEI Pharma, Inc. 34 Meiji Seika Pharma Co., Ltd. 35 Mezzion Pharma Co. Ltd. 36 Monosol Rx LLC 37 Nymox Pharmaceutical Corporation 38 Ogeda SA 39 Ono Pharmaceutical Co., Ltd. 40 SK Chemicals Co., Ltd. 41 SOM Biotech SL 42 Sophiris Bio, Inc. 43 Vantia Therapeutics 44 XuanZhu Pharma Co Ltd 45 Yungjin Pharm. Co., Ltd. 46 Benign Prostatic Hyperplasia - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 (dutasteride + tadalafil) - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 (tadalafil + tamsulosin hydrochloride) - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ADX-68692 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ASC-JM.X2 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 AUS-131 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 BCWPE-004 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 BL-214 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 ESN-364 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 fadanafil - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 fedovapagon - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 fexapotide triflutate - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 HCP-1303 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 HIP-1402 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 KKM-1202 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 L-1AD3 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 MCS-2 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 NCE-403 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 ONO-8430506 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 S-40542 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 SOM-2391 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 SOM-2393 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Sperol - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 tadalafil - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 talaporfin sodium - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 tamsulosin hydrochloride CR - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 tamsulosin hydrochloride DR - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 tamsulosin hydrochloride SR - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 tertomotide - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 topsalysin - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 udenafil - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 YBH-1603 - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 YOB-1604 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 Benign Prostatic Hyperplasia - Dormant Projects 113 Benign Prostatic Hyperplasia - Discontinued Products 116 Benign Prostatic Hyperplasia - Product Development Milestones 117 Featured News & Press Releases 117 Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692 117 May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting 118 Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 118 Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 118 Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 119 Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 119 Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 120 Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 121 Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 121 Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 122 May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 123 Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH 124 Oct 28, 2013: Sophiris Announces First Patients Dosed in the PLUS-1 Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 125 Aug 22, 2013: Nymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial 125 Jul 11, 2013: Nymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial 126 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2016 11 Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Comparative Analysis by Unknown Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2016 22 Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2016 23 Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H2 2016 24 Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H2 2016 25 Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 26 Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2016 27 Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 28 Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 29 Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 30 Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co., Ltd., H2 2016 31 Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 32 Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 33 Benign Prostatic Hyperplasia - Pipeline by MEI Pharma, Inc., H2 2016 34 Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016 35 Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 36 Benign Prostatic Hyperplasia - Pipeline by Monosol Rx LLC, H2 2016 37 Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H2 2016 38 Benign Prostatic Hyperplasia - Pipeline by Ogeda SA, H2 2016 39 Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 40 Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H2 2016 41 Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H2 2016 42 Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H2 2016 43 Benign Prostatic Hyperplasia - Pipeline by Vantia Therapeutics, H2 2016 44 Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 45 Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 46 Assessment by Monotherapy Products, H2 2016 47 Assessment by Combination Products, H2 2016 48 Number of Products by Stage and Target, H2 2016 50 Number of Products by Stage and Mechanism of Action, H2 2016 52 Number of Products by Stage and Route of Administration, H2 2016 54 Number of Products by Stage and Molecule Type, H2 2016 56 Benign Prostatic Hyperplasia - Dormant Projects, H2 2016 113 Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H2 2016 114 Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H2 2016 115 Benign Prostatic Hyperplasia - Discontinued Products, H2 2016 116



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify